The CDC has issued a health alert and the FDA is warning consumers after more than 25 patients across four states fell ill from contaminated IV glutathione products administered at wellness clinics. Three Texas compounding pharmacies have recalled their injectable glutathione products following reports of symptoms consistent with bacterial endotoxin exposure.
At least three patients have been hospitalized, with one requiring intensive care for shock and abnormal blood clotting. Illnesses have been reported in Texas, Washington, Florida, and New York, according to the CDC alert.
The recalled products include Myer’s Cocktail and Tri-Immune Boost, which were sold by Victory Medical Center Pharmacy, Optimal Balance Pharmacy, and Centric Compounding. The FDA noted that the glutathione used in these products was labeled as dietary supplement grade — a classification the agency says is not appropriate for injectable drugs.
What happened
On September 17, 2026, the CDC issued a health alert warning that dozens of patients had been sickened after receiving IV glutathione infusions at wellness clinics. The FDA identified the contaminated glutathione as being labeled dietary-supplement grade rather than pharmaceutical-grade material suitable for injection.
Three Texas compounding pharmacies — Victory Medical Center Pharmacy, Optimal Balance Pharmacy, and Centric Compounding — recalled their glutathione-containing products, including formulations marketed as Myer’s Cocktail and Tri-Immune Boost. Patients reported symptoms consistent with bacterial endotoxin exposure.
Reported illnesses span four states: Texas, Washington, Florida, and New York. At least three people have been hospitalized, and one patient required intensive care for shock and abnormal blood clotting. The CDC and FDA have not yet disclosed the total number of affected patients beyond describing it as dozens.
Why it matters
This event represents a direct patient harm case tied to compounded injectable products administered at wellness clinics, a sector that has drawn increasing regulatory attention in recent years. The recall underscores that compounding quality failures extend beyond GLP-1 peptides — the category that has dominated recent compounding headlines — to other compounded injectables commonly offered at wellness and anti-aging clinics.
The FDA’s statement that the glutathione was labeled as dietary supplement grade raises questions about sourcing and quality control practices at compounding pharmacies. Dietary supplement grade materials are not held to the same purity, sterility, and testing standards as active pharmaceutical ingredients intended for injection.
The incident also highlights that state-licensed pharmacies operating under traditional compounding frameworks are not immune from serious safety events. Consumers receiving IV therapies at wellness clinics may face risks from products that do not go through the standard drug manufacturing and approval process.
What to watch next
- Whether additional pharmacies or clinics are linked to the outbreak as the CDC and FDA continue their investigation
- Potential enforcement actions by the FDA or state pharmacy boards against the named pharmacies
- Whether the investigation prompts broader regulatory scrutiny of compounded IV therapies and wellness clinic practices
- Any updates on the conditions of hospitalized patients and whether additional illnesses are reported
Sources
Industry information only. Not medical or legal advice.
